These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Edbauer D; Haass C Curr Opin Neurobiol; 2016 Feb; 36():99-106. PubMed ID: 26555807 [TBL] [Abstract][Full Text] [Related]
7. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia. Jovičić A; Paul JW; Gitler AD J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014 [TBL] [Abstract][Full Text] [Related]
8. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD. Hayes LR; Kalab P Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708 [TBL] [Abstract][Full Text] [Related]
9. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Janssens J; Van Broeckhoven C Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071 [TBL] [Abstract][Full Text] [Related]
10. Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Pasetto L; Grassano M; Pozzi S; Luotti S; Sammali E; Migazzi A; Basso M; Spagnolli G; Biasini E; Micotti E; Cerovic M; Carli M; Forloni G; De Marco G; Manera U; Moglia C; Mora G; Traynor BJ; Chiò A; Calvo A; Bonetto V Brain; 2021 Dec; 144(12):3710-3726. PubMed ID: 34972208 [TBL] [Abstract][Full Text] [Related]
11. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Ihara R; Matsukawa K; Nagata Y; Kunugi H; Tsuji S; Chihara T; Kuranaga E; Miura M; Wakabayashi T; Hashimoto T; Iwatsubo T Hum Mol Genet; 2013 Nov; 22(22):4474-84. PubMed ID: 23804749 [TBL] [Abstract][Full Text] [Related]
12. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Barmada SJ; Finkbeiner S Rev Neurosci; 2010; 21(4):251-72. PubMed ID: 21086759 [TBL] [Abstract][Full Text] [Related]
13. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. Gao J; Wang L; Yan T; Perry G; Wang X Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085 [TBL] [Abstract][Full Text] [Related]
14. Optogenetic TDP-43 nucleation induces persistent insoluble species and progressive motor dysfunction in vivo. Otte CG; Fortuna TR; Mann JR; Gleixner AM; Ramesh N; Pyles NJ; Pandey UB; Donnelly CJ Neurobiol Dis; 2020 Dec; 146():105078. PubMed ID: 32927062 [TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD. Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763 [TBL] [Abstract][Full Text] [Related]
16. RNA-binding proteins with prion-like domains in health and disease. Harrison AF; Shorter J Biochem J; 2017 Apr; 474(8):1417-1438. PubMed ID: 28389532 [TBL] [Abstract][Full Text] [Related]
17. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. Wang P; Deng J; Dong J; Liu J; Bigio EH; Mesulam M; Wang T; Sun L; Wang L; Lee AY; McGee WA; Chen X; Fushimi K; Zhu L; Wu JY PLoS Genet; 2019 May; 15(5):e1007947. PubMed ID: 31100073 [TBL] [Abstract][Full Text] [Related]
18. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD. Pirie E; Oh CK; Zhang X; Han X; Cieplak P; Scott HR; Deal AK; Ghatak S; Martinez FJ; Yeo GW; Yates JR; Nakamura T; Lipton SA Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33692125 [TBL] [Abstract][Full Text] [Related]
19. RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy. Necarsulmer JC; Simon JM; Evangelista BA; Chen Y; Tian X; Nafees S; Marquez AB; Jiang H; Wang P; Ajit D; Nikolova VD; Harper KM; Ezzell JA; Lin FC; Beltran AS; Moy SS; Cohen TJ Elife; 2023 Oct; 12():. PubMed ID: 37819053 [TBL] [Abstract][Full Text] [Related]
20. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Scotter EL; Chen HJ; Shaw CE Neurotherapeutics; 2015 Apr; 12(2):352-63. PubMed ID: 25652699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]